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Abstract
Background: Extracellular proteases such as plasminogen activators (PAs) and matrix metalloproteinases modulate
cell-cell and cell-matrix interactions. Components of the PA/plasmin system have been shown to be increased in
areas of inflammation, and have been suggested to play a role in inflammatory neurologic disorders such as
epilepsy, stroke, brain trauma, Alzheimer's' disease and multiple sclerosis (MS). In the present study, we evaluated
the involvement of the PA system in the animal model of MS, experimental autoimmune encephalomyelitis (EAE).
Methods: EAE was induced by myelin oligodendrocyte glycoprotein (MOG) in mice deficient for the urokinase PA
(uPA−/−), or the urokinase PA receptor (uPAR−/−). Mice were evaluated for EAE clinical signs and histopathologic
parameters, and compared with wild-type (WT) EAE mice. Lymphocytes from the knockout (KO) and WT mice were
analyzed for ex vivo restimulation, cytokine secretion, and antigen presentation. Finally, WT EAE mice were treated
with PAI-1dp, an 18 amino acid peptide derived from the PA inhibitor protein (PAI-1).
Results: EAE was aggravated in uPA−/− and uPAR−/− mice, and this was accompanied by more severe
histopathologic features and microglial activation. By contrast, specific T- cell reactivity towards the
encephalitogenic antigen MOG was markedly reduced in the KO animals, as shown by a marked reduction in
proliferation and pro-inflammatory cytokine secretion in these mice. Antigen presentation was also reduced in all
the KO animals, raising an immunologic paradox. When the mice were treated with PAI-1, a peptide derived from
the PA system, a marked and significant improvement in EAE was seen. The clinical improvement was linked to
reduced T-cell reactivity, further emphasizing the importance of the PA system in immunomodulation during
neuroinflammation.
Conclusions: Cumulatively, our results suggest a role for uPA and uPAR in EAE pathogenesis, as exacerbation of
disease was seen in their absence. Furthermore, the successful amelioration of EAE by PAI-1 treatment suggests that
the PA system can be considered a potential site for therapeutic intervention in the treatment of neuroimmune
diseases.
Introduction
Extracellular proteolysis represents a potent and irrevers-
ible mechanism of extracellular matrix remodeling [1]. It
is involved in physiologic processes and in several patho-
logic conditions such as tumor invasion, inflammation,
tissue repair, and excitoxicity [2,3]. Cumulative data have
suggested that extracellular proteolysis plays a crucial role
in the pathophysiology of neuronal cell death. Deleterious
effects include disruption of the blood–brain barrier
(BBB), amplification of inflammatory infiltrates, demyelin-
ation, and possibly disruption of cell-cell and cell-matrix
interactions, which may trigger cell death. The positive ef-
fects of extracellular proteolysis include mediation of par-
enchymal and angiogenic recovery after brain injury [4].
The major extracellular proteolytic enzymes are the
plasminogen activator (PA)/plasmin system and the
matrix metalloproteinases (MMPs). PAs, specifically
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tissue PA (tPA) and urokinase-type PA (uPA), are serine
proteases that cleave the zymogen plasminogen to gen-
erate the proteolytic enzyme plasmin. The PA/plasmin
system has been implicated in fibrin removal, and in tis-
sue remodeling and cell migration that occur during
physiologic and pathologic processes [5], neurotoxicity,
neuroprotection, and cerebral blood flow [5].
Studies on peripheral nerve injury have shown that fi-
brin deposition is a factor impeding axonal regeneration,
whereas fibrin removal is associated with restoration of
axonal function [6,7]. By contrast, activation of extracellu-
lar proteolysis is considered a pathogenic factor in demye-
linating disorders such as multiple sclerosis (MS) and its
animal model, experimental autoimmune encephalomyelitis
(EAE). MS, an immune-mediated disease of the central
nervous system (CNS), is characterized by chronic inflam-
matory processes. It involves the activation of CNS-
immunocompetent cells and microglia, and extravasation
of T cells and macrophages [8].
There is an ample body of literature regarding the in-
volvement of PAs in neurologic disorders. Specifically,
PA activity in MS is considered to play a major role
in disturbance of the BBB and subsequent leukocyte
migration, leading to inflammation, and causing myelin
breakdown [9]. One of the earliest detectable signs of in-
flammatory demyelination is upregulation of urokinase
type PA receptor (uPAR) and PA inhibitor (PAI-1). In
the demyelinating MS lesion, tPA and uPA, forming a
complex with PAI-1, are prominent in foamy macro-
phages, and are also a component of the MMP cascade.
Significant parallel increases in components of the uPA sys-
tem have been seen in MS tissue, with immunolocalization
to macrophages in the active lesion, and mononuclear cells
in the perivascular cuff [4,10]. Microglial cells isolated from
the white matter of post-mortem MS tissue also have
detectable uPAR [4,11]. Co-localization of uPAR with
integrins on macrophages in the lesion further promotes
adhesion to vitronectin, which in turn, leads to focal
increases of PA activity [10]. During clinical EAE, the PA
system was shown to be upregulated in the CNS as well
[12]. Induction of tPA expression and of the PAI-1
transcript was detected in activated astrocytes in white
matter. Inflammatory cells expressing uPAR also
showed increased tPA and uPA activities in areas of
inflammatory damage [12].
Activity of the PA system components is monitored
closely and regulated by serine proteinase inhibitors, of
which PAI-1 is most prominent. PAI-1 binds to active
uPA and forms an uPA-PAI-1 complex, which is
followed by the internalization and intracellular deg-
radation of the complex [13].
In this study, we investigated the role of uPA and
uPAR in EAE induced by myelin oligodendrocyte glyco-
protein (MOG), by using uPA and uPAR knockout (KO)
mice and comparing them with their wild-type (WT)
counterparts. We found that the PA system affected the
severity of EAE, with uPA−/− and uPAR−/− mice develop-
ing a more severe clinical course. The extent of inflam-
mation, axonal loss, and axonal injury correlated with
the more severe clinical outcome. Furthermore, pre-
treating EAE mice with a PAI-1-derived peptide, (PAI-1-
dp) [14] suppressed the development of EAE. Thus, our
results support the importance of the PA components




C57BL/6 mice were purchased from Harlan Laboratories
Ltd, Ein Kerem Breeding Farm, Jerusalem, Israel, and
housed under specific pathogen-free conditions in the
animal facility of the Hebrew University Medical School,
Jerusalem, Israel, in accordance with National Institutes
of Health (NIH) guidelines for the care and use of la-
boratory animals. KO mice deficient for uPA and uPAR
against a C57BL/6 background were purchased (Jackson
Immunoresearch Laboratories, West Grove, PA, USA),
bred in the animal facility of the Hebrew University
Medical School, and housed under specific pathogen-
free conditions.
EAE induction and clinical evaluation
EAE was induced in 8-week-old female C57BL/6 mice
by subcutaneous injection into the left paralumbar re-
gion of 125 μg MOG 35–55 peptide (synthesized by
Sigma Laboratories, Israel) that had been emulsified in
complete Freund’s adjuvant (CFA) containing 5 mg/ml
heat-killed Mycobacterium tuberculosis. Immediately
after this injection and, again 48 h later, the mice were
inoculated intraperitoneally with 0.5 ml pertussis toxin
(200 ng). An additional injection of MOG35-55 peptide
in CFA was delivered 7 days later into the right
paralumbar region.
All the animals were examined daily and evaluated for
clinical signs of disease. The clinical status of the mice
was graded as follows: 0, without clinical disease; 1, tail
weakness; 2, hind limb weakness sufficient to impair
righting; 3, single-limb plegia; 4, paraplegia with forelimb
weakness; 5, quadriplegia; 6, death. According to the
ethical requirements, mice that reached stage 4 were
euthanaized.
PAI-1-dp pre-treatment
An 18 amino acid peptide, Ac-RMAPEEIIMDRPFLYVVR-
amide [14], derived from the PAI-1 protein (PAI-1-dp), was
used for pre-treatment of mice induced with EAE (n = 16)
and these were compared with control placebo-treated
mice (n = 16). PAI-1-dp 0.5 mg/kg was injected
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intraperitoneal twice daily, starting 1 day preceding disease
induction, and continued for 7 consecutive days. Mice were
followed clinically as described above.
Histopathology
Between days 17 and 25 post-induction, animals were
transcardially perfused with paraformaldehyde in PBS (pH
7.2). The brains and spinal cords were removed, post-fixed
in the same fixative, sectioned, and routinely processed for
paraffin wax embedding and sectioning at 6 μm (coronal
brain and longitudinal spinal-cord sections). The sections
were then stained with a modified Bielschowsky silver im-
pregnation combined with hematoxylin for simultaneous
evaluation of axonal injury, axonal loss and infiltration, as
previously described in detail [15,16].
Pathologic examination was performed under a light
microscope (Axioplan-2; Zeiss), by two investigators
blinded to the study groups. Photographs were captured
with the aid of a digital camera (Nikon) attached to the
microscope. For each animal, 10 randomly selected sections
per tissue type (hemispheres, brain stem, cerebellum, and
spinal cord), spaced at least 60 μm apart, were examined
under high-power optical fields, using a prefrontal micro-
scope grid as previously described [15]. Sections containing
both gray and white matter were stained with hematoxylin
and eosin. Inflammatory foci containing at least 20 perivas-
cular mononuclear cells were assessed in each section. The
number of perivascular and parenchymal infiltrates were
counted, and the data were recomputed as infiltrates/mm2.
Axonal injury (AI) was graded using the following scale 0,
normal; 1+, a few scattered injured axons; 2+, focal mild to
moderate AI; 3+, scattered mild to moderate AI or focal
severe AI; 4+, scattered severe AI. Axonal loss (AL) was
graded as: 0, normal; 1+, focal mild to moderate AL; 2+,
scattered mild to moderate AL; 3+, focal severe AL and 4+,
scattered severe AL.
Microglial staining
Lectin-positive microglia/macrophages were detected in
brain and spinal-cord sections using histochemical
staining with biotin-labeled lectin (Sigma Aldrich, St.
Louis, MO, USA) originating from Lycopersicon esculent
(tomato), as previously described [15]. This molecule
has been used previously for identifying microglia/
macrophages and in revealing their morphology [17].
Briefly, sections were dewaxed, dried with ethanol,
and treated with proteinase K (Clontec Laboratories,
Mountain View, CA, USA) for 2.5 minutes at 37°C,
followed by treatment with 0.3% H2O2 for 15 min and
further incubation with 0.3% Triton-X in Tris-buffered
saline containing an avidin-biotin blocking agent
(Vector Laboratories, Burlingame, CA, USA). The sec-
tions were then incubated with the biotin-labeled lectin
(3 μg/ml) for 2 hours at room temperature, and streptavidin
was added to permit visualization with an appropriate
chromogen (NovaRed; Vector Laboratories).
The lectin-positive microglia/macrophages were read-
ily identified and morphologically distinguishable from
blood vessels, which this molecule also stains [17,18].
The number of lectin-positive microglia/macrophages
was counted, and the data were recomputed as lectin-
positive cells/mm2.
Lymphocyte proliferation assay
Pooled lymph-node cells (LNCs) were prepared from in-
guinal, axillary, and mesenteric lymph nodes or spleens
derived from naive mice or from mice that had been
subcutaneously inoculated 9 days earlier with MOG 35–55
peptide in CFA. The in vitro response of the lymphocytes
was assayed in triplicate wells of 96-well flat-bottom micro-
titer plates. A total of 2 × 105 LNCs, suspended in 0.2 ml
RPMI supplemented with 5% FCS, was added to each well
with or without 100 μg/ml MOG 35–55 peptide. At 48 h
after seeding, 1 μCi 3[H]thymidine (Amersham Pharmacia
Biotech, Amersham, Buckinghamshire, UK) was added
to each well, and the plates were incubated for an
additional 18 h. The plates were then harvested with a
semi-automated harvester onto a glass fiber filter, and
the radioactivity was determined by liquid scintillation
assay.
Antigen presentation assay
Antigen-presenting cells (APCs) were derived from
spleens of WT, uPA−/− or uPAR−/− naive mice. Before
co-culture with responder T cells, the splenocytes were
irradiated at 3000 rad, so that the proliferation in the
co-culture assays could be attributable solely to the re-
sponder T cells. The latter were obtained from MOG35–55-
stimulated LNCs derived from MOG-immunized WT
mice. The cells were maintained in MOG-containing
medium for 4 days, after which the medium was
replenished and supplemented with interleukin (IL)-2
(20 μg/ml) for an additional 5 days. For the antigen
presentation assay, 50,000 responder T cells (per well)
were co-cultured with 300,000 irradiated splenocytes
derived from WT, uPA−/− or uPAR−/− naive mice, in the
presence of MOG (50 μg/ml) for 72 h. The cells were cul-
tured in RPMI 1640 containing 10% FCS supplemented
with 5 × 10−5 mol/l 2-ME, 1 mmol/l sodium pyruvate,
1/100nonessential amino acids, 2mmole/L L-glutamine 2,
and 100 U of penicillin/ml (Austria). Responder T-cell
proliferation was assessed by [3H] thymidine incorporation.
Statistical analysis
The histopathologic data were analyzed using SPSS
software (version 18.0). The values of all the data are
expressed as mean ± standard error (SE). Semi-quantitative
data for the two groups (AI and AL) were analyzed using
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the Pearson χ2 test or Fisher’s exact test, where appropriate,
and the data were displayed as bar graphs. The differ-
ence between the two groups was compared using the
Mann–Whitney U-test or Student's t-test, as appropri-
ate. The remaining data were analyzed using Student's
t test and one-way ANOVA, according to Dunnett, and
Fisher’s exact test. P<0.05 was considered significant.
Results
Aggravation of EAE in uPA−/− and uPAR−/− mice
Several components of the plasminogen activation cas-
cade have been found to be involved in CNS pathologies,
including stroke, TBI, MS, and EAE. To evaluate the
effect of uPA and uPAR on processes related to CNS
inflammation, we examined their involvement in EAE,
the experimental inflammatory and demyelinating auto-
immune disease used to study human MS. EAE was
induced in uPA−/− , uPAR−/−, and WT mice. All the KO
mice tested presented more severe neurologic scores
and delayed recovery compared with the WT mice
(Figure 1). In the uPA−/− mice, the mean disease severity
was 1.8 ± 0.2 compared with 1.1 ± 0.2 in the WT mice
(a 64% increase) (Figure 1A). uPAR−/− mice had signifi-
cantly more severe disease than the WT mice in the
chronic phase of the disease (Figure 1B), with mean dis-
ease severity being 2.5 ± 0.4 for uPAR−/− versus 1.7 ± 0.2
for WT (a 47% increase over WT) (Figure 1B). Notably,
whereas the WT mice showed remission of the disease
about 30 days post-induction, both the uPA−/− and the
uPAR−/− animals failed to recover.
Neuropathologic parameters in uPA−/− and uPAR−/− mice
The marked difference in the clinical score of the uPA−/−
and uPAR−/− animals was consistent with the neuropatho-
logic processes in their spinal cords during the chronic
phase of the disease. Evaluation of cellular infiltration (infil-
trates/mm2), AI, and AL identified a massive infiltration of
mononuclear cells in the spinal cords of the uPA−/− animals
(Figure 2A) accompanied by a marked increase in AI and
AL (Figure 3B and D) compared with WT EAE mice
(P<0.001, p<0.05, p<0.001 respectively). Concomitantly, the
uPA−/− group exhibited severe AI with more ovoids, spher-
oids, and dystrophic axons, even in areas without striking
perivascular infiltration, but displayed only some parenchy-
mal infiltrates compared with the corresponding WT con-
trols (Figure 2a1,a2). Milder differences were noted in the
brainstem, cerebelli, and hemispheres of the animals (data
not shown).
Similarly, the uPAR−/− mice exhibited an increased in-
flammatory burden in their spinal cords (Figure 2B)
(p<0.05) and a marked AL (Figure 3C) (P<0.001), albeit
with similar levels of AI (Figure 3A) during the chronic
phase, compared with the WT EAE-induced mice. These
neuropathologic data are in agreement with the clinical
courses of the KO and WT animals, which displayed a
similar acute phase and a different chronic phase.
Microglia and blood-borne macrophages play an im-
portant role in EAE pathogenesis. Evaluation of activated
lectin-positive microglia/macrophages per mm2 during
the chronic phase of the disease showed a twofold
increase within the spinal cords of the uPAR−/− mice
compared with the WT control mice (Figure 4).
Immune responses to MOG35-55 and antigen presentation
in uPA−/− and uPAR−/− mice
In all the described models of EAE, the cells that initiate
the disease are predominantly myelin-reactive CD4+ T
helper cells. These antigen-specific autoimmune T cells first
contact a naive intact BBB, and are able to extravsate
through the BBB, because of their active status. In the CNS,
as a result of presentation of appropriate antigens, the cells
undergo further activation.
To assess the differences between the KO mice and
the WT mice, we performed two sets of experiments:
Figure 1 Experimental autoimmune encephalomyelitis (EAE) is aggravated in mice deficient for the urokinase plasminogen activator
(uPA−/−), or the urokinase plasminogen activator receptor (uPAR−/−). (A) EAE clinical severity in uPA−/− mice and control wild-type (WT)
mice. (B) EAE clinical severity in uPAR−/− mice and control WT mice. (A,B) Results are expressed as the mean clinical score ± standard error (SE)
of three separate experiments (*P<0.05).
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T-cell activation, evaluated by T-cell proliferation and
pro-inflammatory cytokine secretion, and an antigen-
presenting assay. Unexpectedly, and unrelated to disease
severity, the T-cell reactivity towards the encephalito-
genic MOG35–55 peptide of cells derived from the
uPA−/− and uPAR−/− mice was found to have a signifi-
cantly lower response to the tested antigen compared
with WT cells. This presented as reduced proliferation
of MOG35–55 encephalitogenic cells (Figure 5A), and re-
duced secretion of pro-inflammatory cytokines. Absence
of uPA resulted in a 57% reduction in IFN-γ secretion
and a 62% reduction in tumor necrosis factor (TNF)-α
(Figure 5B,C). Similarly, in the absence of uPAR, a 70%
reduction in IFN-γ secretion and a 45% reduction in
TNF-α secretion were seen.
We then examined the ability of APCs cultured from
uPA−/− and uPAR−/− mice to mount an immunologic re-
action compared with APCs from WT animals. APCs
were prepared from uPA−/−, and uPAR−/−, and WT ani-
mals (as described in Materials and Methods), and
plated with anti–MOG35-55-specific lymphocytes in the
presence of MOG35-55. Figure 5D shows a reduction in
lymphocyte proliferation in the presence of APCs from













Figure 2 Neuropathology in the spinal cords of EAE in urokinase plasminogen activator (uPA−/−), or the urokinase plasminogen
activator receptor (uPAR−/−) mice compared with WT mice. The results are presented as mean ± standard error (SE) (infiltrates/mm2). (A) uPA
−/− animals exhibited an almost twofold greater inflammatory burden (**P<0.001). (a1,a2) Representative photographs (hematoxylin plus
Bielschowsky stain) Magnification x200. (B) uPAR−/− animals exhibited significantly greater inflammation (*P<0.05). (b1,b2) Representative
photographs, magnification x200.
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WT animals. The results indicate a reduction in antigen
presentation capacity in the uPA−/− and uPAR−/− animals.
Amelioration of EAE after PAI-1 administration
Cumulatively, these results suggest that in addition to
their effect on the inflammatory system, uPA and
uPAR play other protective roles. Indeed, uPA and
uPAR are known to initiate and stimulate the fibrino-
lytic system, suggesting that, in sum, the balances of
their effects are neuroprotective. In an attempt to in-
hibit the deleterious, pro-inflammatory effects of the
lack of uPA and uPAR, and to increase their pro-
fibrinolytic effect, we injected the animals with the
PAI-1-derived 18 amino acid peptide (PAI-dp). This
peptide correlates with the docking site of PAI-1
within the uPA protein. Binding of the peptide to uPA
prevents binding of the intrinsic PAI-1 to uPA, thereby
preventing the inhibitory effect of PAI-1. We previ-
ously reported that PAI-dp inhibits the binding of uPA
to PAI-1 and in so doing, increases the plasminogen
activation ability of uPA, and inhibits uPA-induced sig-
nal transduction [14].
Figure 3 Axonal injury and axonal loss in experimental autoimmune encephalomyelitis (EAE) in mice deficient for the urokinase
plasminogen activator (uPA−/−), or the urokinase plasminogen activator receptor (uPAR−/−) compared with EAE wild-type (WT) mice.
Rsults are presented as percentage distribution of severity. (A,C) uPAR−/− mice exhibited (A) similarly active axonal injury (AI) and (C) significantly
greater axonal loss (AL). (B,D) uPA−/− mice exhibited (B) more severe AI and (D) more AL. *P<0.05, **P<0.001.
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WT mice induced with EAE were injected with PAI-
1dp, and compared with placebo-injected EAE mice. As
seen in Figure 6, preventative administration of PAI-dp
markedly and significantly suppressed the disease, with
disease severity being reduced by 83% (from 1.2 ± 0.3 to
0.2 ± 0.04). Furthermore, T-cell reactivity towards the
encephalitogenic MOG35–55 peptide was reduced in the
PAI-1dp-injected mice. As shown in Figure 7, T-cell
proliferation was reduced (Figure 7A) in lymphocytes
derived from PAI-1-injected mice. Accordingly, the pro-
inflammatory cytokines IFN-γ and IL-17 were also re-
duced in these mice (Figure7B).
Discussion
The data presented in this study show that the PA sys-
tem plays a role in CNS inflammation. Using mice lack-
ing uPA and uPAR, we found that during EAE, mice
exhibit a very severe disease, with impaired recovery.
The neuropathologic findings were consistent with
disease severity; uPA−/− and uPAR−/− mice showed an
increase in AL and a massive infiltration of mononuclear
cells into the spinal cord.
In addition, the importance of microglial activation in
EAE pathology is known, and we found that microglial
activation was increased twofold within the spinal cord
of uPAR−/− mice. Microglia are resident APCs that make
up to 10 - 20% of all the glial cells in the CNS [19]. In
MS and EAE, microglia are activated, express high levels
of major histocompatibility complex class II, and
function as APCs [20,21]. The increase in lectin-positive
microglia/macrophage activation seen in the uPAR−/−
animals is in accordance with the clinical severity of the
disease.
Our results are in agreement with previously reported
results. East et al. reported a more severe EAE in tPA−/−
mice, characterized by incomplete recovery and in-
creased neurologic deficit, and also reported persisting
inflammatory cuffs of mononuclear cells and a greater
degree of demyelination in uPAR−/− mice [9]. Another
report by East et al. showed that mice lacking the
plasminogen inhibitor PAI-1 developed milder EAE
without clinical relapse, and with an overall reduction in
neuroinflammation [22].
These findings, together with those from the earlier part
of the current study, prompted us to attempt to treat EAE
using the PAI-dp, the peptide derived from the PAI-1 pro-
tein. PAI-1dp inhibits the action of PAI-1, thereby
prolonging the presence and proteolytic activity of uPA.
Importantly, we found that when EAE mice were pre-
treated with PAI-1dp, they developed a markedly less severe
disease, accompanied by a reduction in T-cell reactivity. To
our knowledge, this amelioration of EAE after the novel ap-
proach of injecting peptides derived from the PA system
has not been reported previously.
The roles played by the PA system in the pathogenesis
of EAE could be ascribed to a number of different mech-
anisms, such as regulation of fibrin deposition at sites of
inflammation, and effects on cell trafficking into the
Figure 4 Lectin-positive microglia/macrophages in spinal cords of mice deficient for the urokinase plasminogen activator receptor
(uPAR−/−) and of wild-type (WT) mice. (A) Significant increase in numbers of lectin-positive cells (microglia/macrophages) in the spinal cords of
uPAR−/− animals compared with the WT mice (***P<0.0001). Representative photographs showing perivascular and parenchymal lectin-positive
microglia/macrophages (arrows) in (B,C) WT and (D,E) uPAR−/− animals.
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CNS. Fibrin, the end product of PA proteolytic activity,
participates in a variety of cellular responses associated
with inflammation [23,24] by binding to a range of re-
ceptors that are expressed on leucocytes, macrophages,
and monocytes [25]. Fibrinogen-deficient mice show de-
layed inflammatory responses to lipopolysaccharide [26].
Because fibrin is capable of modulating inflammation via
a number of different mechanisms, it is clear that re-
moval of fibrin by enhancing fibrinolysis can produce
beneficial results.
Although the uPA−/− and uPAR−/− mice exhibited
more severe disease, there was a reduction in their im-
mune response compared with WT mice. This was
reflected by a reduction in proliferative lymphocytes and
a reduced ability to present antigen. These findings point
to a paradoxical situation in which the KO mice present
with more severe disease, a condition that is usually
characterized by high lymphocyte proliferation and
cytokine induction, but in this study showed just the
opposite results. The PA system is considered to be both
pro-inflammatory and anti-inflammatory. The former is
related to the mounting of correct innate and adaptive
immune responses, whereas the latter is related to pre-
vention of extracellular fibrin deposition [13]. The PA
system components involvement in two opposing pro-
cesses might explain these conflicting results.
There is an intriguing link between the uPA/uPAR
system and the immune system. Both uPA and uPAR
expression were shown to be modulated by inflamma-
tory mediators. TNF-α, IFN-γ, and IL-1 were found
to increase uPA expression on macrophages [27,28].
Activated T lymphocytes express uPA and uPAR [29,30],
and stimulation with phorbol esters and T-cell recep-
tor (TCR)-mediated stimulation results in substantial
upregulation of uPA and uPAR in T cells [31]. uPAR is
co-expressed with CD25 (IL-2R), and its expression in
TCR-mediated T-cell activation has been established
















































































































Figure 5 mice deficient for the urokinase plasminogen activator (uPA−/−), or the urokinase plasminogen activator receptor (uPAR−/−)
show reduced T-cell reactivity to myelin oligodendrocyte glycoprotein (MOG)35–55 and reduced antigen presentation. (A) Proliferation
of lymphocyte from all the tested groups was checked by [3H] thymidine incorporation in the presence of MOG35-55. (B). The effect of uPA and
uPAR deficiency on T helper 1 (Th1) cytokine secretion. Lymphocytes from uPA−/−, uPAR−/− and WT mice were stimulated with MOG35-55, the
media were collected after 24 hours, and the secreted (B) interferon (IFN)-γ and (C) tumor necrosis factor (TNF)-α were measured by ELISA. (A–C)
Results are expressed as mean ± standard error (SE) of three separate experiments (*P<0.05) (D) Effect of uPA and uPAR deficiency on antigen
presentation measured by MOG35-55 specific T-cell proliferation. Lymphocyte proliferation was checked by [
3H] thymidine incorporation
using APCs from knockout (KO) or WT mice in the presence of MOG35-55. Results are expressed as the mean ± SE of four separate
experiments (*P<0.05).
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IL-2 and IL-4, but not to several other cytokines [33].
Conversely, there is substantial evidence suggesting
that uPA is a modulator of immune and inflammatory
responses. For example, early reports showed that PA
could act as a lymphocyte mitogen [32]. Thus, bidirec-
tional communication links the uPA/uPAR system and
the inflammatory cytokine networks. Therefore, the
profound effect of uPA/uPAR deficiency on lympho-
cyte activation in our model is not unexpected, and the
severe clinical outcome can be explained by the inabil-
ity of the KO mice to mount a protective immune re-
sponse. Similar results were reported by Gyetko et al.
[34] who investigated the ability of uPA−/− mice to
mount a protective host defense during infection with
the opportunistic yeast Cryptococcus neoformans. In
the absence of uPA, the mice failed to mount an
adequate immune defense against the yeast, resulting
in a lethal defect in cell-mediated immune responses.
When targeting the PA system for treatment of EAE/
MS, it is important to bear in mind its major role in
the fibrinolytic system, and that manipulation of the
PA system might cause unwanted effects in the coagu-
lation/fibrinolytic system. Recombinant tPA has been
in clinical use for treatment of myocardial infarct.
However, it can be given only once in such cases,
and not as an ongoing treatment because it causes
excessive bleeding, and therefore cannot be used for
treatment of MS.
It is interesting that mice lacking uPA do not have
































* * * *
** * * ** * * ** **
Figure 6 Administration of the plasminogen activator inhibitor-derived peptide PAI-1dp ameliorated the clinical course of
experimental autoimmune encephalomyelitis (EAE). EAE was induced in wild-tupe (WT) mice by immunization with myelin oligodendrocyte
glycoprotein (MOG)35–55. The animals were given either placebo or PAI-dp 0.5 mg/kg twice daily by intraperitoneal injection. Results are


































































Figure 7 Administration of PAI-1dp reduces T-cell reactivity towards MOG35-55 peptide. A. PAI-1dp pre-treatment reduced T cell
proliferation induced by MOG35-55. B. Reduced secretion of the pro-inflammatory cytokines IFN-γ and IL-17. The results are the mean standard
error (SE) of three separate experiments (*P<0.05).
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because of the redundant fibrinolytic function of uPA,
which, at least in the vascular compartment, can be
substituted for by tPA. Double uPA-tPA KO mice
show extensive thrombotic disorders similar to those in
plasminogen KO mice [36]. In addition, disruption of
the PAI-I gene in mice does not appear to impair
hemostasis, but is associated with increased resistance to
thrombosis and with a mild hyperfibrinolytic state char-
acterized by enhanced in vivo clot lysis [37]. Interest-
ingly, despite the minor influence of the disruption of
these genes in the naïve state, the effects of disruption
become apparent upon disease induction. This suggests
that the biologic consequences of PA system gene inacti-
vation might be more significant in disease states.
Conclusions
It is probable that the PA system plays both harmful and
beneficial roles in MS/EAE, and that there is a balance
between injury and recovery. This balance may be regu-
lated via the expression and secretion of cytokines and
proteolytic enzymes. Our results suggest that attenuation
of uPA activity by pre-treatment with PAI-1-dp may be a
potential mechanism for treatment of CNS inflammatory
and demyelinating diseases.
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